Silence Therapeutics PLC Holding(s) in Company (7589K)
January 06 2021 - 4:08AM
UK Regulatory
TIDMSLN
RNS Number : 7589K
Silence Therapeutics PLC
06 January 2021
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to
the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying Silence Therapeutics plc
issuer
of existing shares to which voting rights
are
attached ii :
1b. Please indicate if the issuer is a non-UK issuer (please mark with
an "X" if appropriate)
Non-UK issuer
---
2. Reason for the notification (please mark the appropriate box or boxes
with an "X")
An acquisition or disposal of voting rights x
---
An acquisition or disposal of financial instruments
---
An event changing the breakdown of voting rights
---
Other (please specify) iii :
---
3. Details of person subject to the notification obligation iv
Name LOIM Lombard Odier Asset Management (Europe)
Limited
--------------------------------------------------------
City and country of registered office London, United Kingdom
(if applicable)
--------------------------------------------------------
4. Full name of shareholder(s) (if different from 3.) v
Name
--------------------------------------------------------
City and country of registered office
(if applicable)
--------------------------------------------------------
5. Date on which the threshold 04/01/2021
was crossed or reached vi :
6. Date on which issuer notified 05/01/2021
(DD/MM/YYYY):
--------------------------------------------------------
7. Total positions of person(s) subject to the notification obligation
% of voting rights % of voting rights Total of both Total number
attached to shares through financial in % (8.A + 8.B) of voting
(total of 8. A) instruments (total rights of
of 8.B 1 + 8.B issuer vii
2)
------------------- --------------------- ----------------- --------------
Resulting situation
on the date on
which threshold
was crossed or
reached 10.96% 1.94% 12.90% 83,306,259
------------------- --------------------- ----------------- --------------
Position of previous
notification (if
applicable) 12.80% 0.21% 13.01%
------------------- --------------------- ----------------- --------------
ISIN CODE (if possible)
GB00B9GTXM62 Ordinary
SUBTOTAL 8. A
8. Notified details of the resulting situation on the date on which the
threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of Number of voting rights ix % of voting rights
shares
ISIN CODE (if
possible)
Direct (Art 9 of Indirect (Art Direct (Art 9 Indirect (Art
Directive 10 of Directive of Directive 10 of Directive
2004/109/EC) (DTR5.1) 2004/109/EC) (DTR5.2.1) 2004/109/EC) 2004/109/EC)
(DTR5.1) (DTR5.2.1)
GB00B9GTXM62 Ordinary 9,130,523 10.96%
----------------------- ------------------------ ----------------------- ----------------
SUBTOTAL 8. A 9,130,523 10.96%
------------------------------------------------- -----------------------------------------
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC
(DTR5.3.1.1 (a))
Number of voting % of voting rights
Type of financial Expiration Exercise/ rights
instrument date x Conversion Period that may be acquired
xi if
the instrument
is
exercised/converted.
ADR US82686Q1013 1,620,000 1.94%
------------------
SUBTOTAL 8. B 1 1,620,000 1.94%
-------------------- --------------------- ------------------
B 2: Financial Instruments with similar economic effect according to Art.
13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial Expiration Exercise/ Physical Number of voting % of voting rights
instrument date x Conversion or cash rights
Period xi settlement
xii
CASH
---------- ----------- ----------- ---------------- ------------------
SUBTOTAL
8.B.2
----------- ---------------- ------------------
9. Information in relation to the person subject to the notification obligation
(please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled by any x
natural person or legal entity and does not control any other undertaking(s)
holding directly or indirectly an interest in the (underlying) issuer
xiii
----
Full chain of controlled undertakings through which the voting rights
and/or the financial instruments are effectively held starting with the
ultimate controlling natural person or legal entity xiv (please add additional
rows as necessary)
----
Name xv % of voting rights % of voting rights Total of both if
if it equals or through financial it equals or is higher
is higher than the instruments if than the notifiable
notifiable threshold it equals or is threshold
higher than the
notifiable threshold
--------------------- --------------------- -------------------------
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights
will be held
11. Additional information xvi
Place of completion London
Date of completion 05/01/2021
----------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
HOLUNRRRAVUARAR
(END) Dow Jones Newswires
January 06, 2021 05:08 ET (10:08 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2023 to Apr 2024
Real-Time news about Silence Therapeutics Plc (London Stock Exchange): 0 recent articles
More Silence Therapeutics Plc News Articles